MiR-33 inhibitors and uses thereof to decrease inflammation

US9241950B2 · kind B2 · utility

Assignee

• NEW YORK UNIVERSITY · US

Inventors

• Kathryn J. Moore · Westfield, US
• Katey Rayner · New York, US
• Frederick Sheedy · New York, US
• Carlos Fernandez-Hernando · New Haven, US
• Yajaira Suarez · New York, US

Key dates

• Filing date: Apr 30, 2012
• Grant date: Jan 26, 2016
• Expiry date: Apr 30, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/3231
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The inhibition of miRNA miR-33 is shown to promote the polarization of macrophages from an M1 to an M2 phenotype. MiR-33 inhibitors are therefore useful for treating inflammation in subjects. Endogenous microRNAs can be silenced using antagomirs. The miR-33 inhibitor is preferably an antagomir having a single-stranded nucleic acid sequence that is complementary to at least 12 contiguous nucleotides in miR-33 and therefore forms a duplex with miR-33 under physiological conditions.